This trial is active, not recruiting.

Condition cardiovascular disease
Treatment cardiac mri
Sponsor Cedars-Sinai Medical Center
Collaborator National Heart, Lung, and Blood Institute (NHLBI)
Start date September 2008
End date August 2020
Trial size 433 participants
Trial identifier NCT00832702, 5R01HL090957, IRB# 14906


This research study is designed to investigate the approaches to noninvasive detection and assessment of coronary vascular dysfunction in women by comparing the testing results from the invasive standard care diagnostic procedure Angiogram and from the additional noninvasive diagnostic procedure CMR Imaging. The investigators want to specifically study 375 female patients who have signs or symptoms suggestive of heart disease but don't have obstructive coronary artery disease. Two study sites (Cedars-Sinai Medical Center and University of Florida) are recruiting participants.

The standard of care procedures include demographics, review of recent clinical symptoms, review of medications being taken, a physical exam, pre-angiogram blood collection, chest x-ray, ECG and heart angiogram. The research procedures for this study are the cold pressor testing, blood/urine collection, health questionnaire, the post-angiogram ECG and cardiac MRI.

Patients will be asked to undergo heart angiogram testing to test for abnormalities in their heart arteries. If the heart angiogram shows that the patients do not have blockages in major heart arteries, then the patients will have coronary flow reserve measurement test (as part of the heart angiogram) to determine whether the patients have abnormally functioning of the small heart arteries. This test will be performed by infusing the three drugs: adenosine, acetylcholine and nitroglycerin. The three drugs are naturally occurring substances and have been used for routine heart angiograms.

Cardiac Magnetic Resonance (CMR) imaging may help us more easily and non-invasively detect abnormalities in the inner layer of the heart muscle resulting from the abnormal function of the heart arteries. All the 375 participants will undergo baseline CMR imaging test and a subgroup of 200 participants will undergo a second CMR imaging test at their at least 1-year followup visit.

Patients will be followed up using phone questionnaires at 6 weeks, 6 months for 5 years, and than annually for 20 years thereafter. Other procedures in this study include obtaining informed consent, review of demographics, physical examination, ECG, blood and urine tests, clinical symptoms, medications, questionnaires, etc. The core laboratories include Blood, Lipoprotein, Chemistry Core Lab, Reproductive Hormone Core Lab, Inflammatory Marker Core Lab, Oxidative Stress Core Lab, and Angiographic Core Lab. Additionally, GCRC at Cedars Sinai will process, store and ship samples as needed/required.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model other
Time perspective prospective

Primary Outcomes

Abnormal cardiac magnetic resonance imaging (CMRI)
time frame: 1 year

Secondary Outcomes

Resource utilization and costs
time frame: up to 20 years
Persistent Chest Pain Symptoms
time frame: up to 20 years
Quality of Life Outcomes
time frame: up to 20 years

Eligibility Criteria

Female participants from 18 years up to 85 years old.

Inclusion Criteria: 1. Symptomatic angina or anginal equivalent; 2. Aged 18 years or older; 3. No obstructive CAD at coronary angiography (performed within the previous 24 months). 4. Competent to give informed consent. Exclusion Criteria: 1. Obstructive CAD ≥ 50% luminal diameter stenosis in ≥ 1 epicardial coronary artery, 2. Acute coronary syndrome (defined by the ACC/AHA criteria, Braunwald 2000), 3. Primary valvular heart disease clearly indicating the need for valve repair or replacement; 4. Patients with concurrent cardiogenic shock or requiring inotropic or intra-aortic balloon support; 5. Prior or planned percutaneous coronary intervention or CABG, 6. Acute MI; 7. Prior non-cardiac illness with an estimated life expectancy < 4 years; 8. Unable to give informed consent; 9. Chest pain with a non-ischemic etiology (e.g.,pericarditis, pneumonia, esophageal spasm); 10. Contraindications to CMRI (e.g., AICD, pacemaker, untreatable claustrophobia or known angio-edema). 11. Contraindications to adenosine or Regadenoson (Lexiscan) 12. Women with intermediate coronary stenoses (> 20% but < 50% luminal diameter stenosis assessed visually at the time of angiography) will undergo clinically indicated IVUS testing based on the judgment of the operator; those determined to have flow-obstructing stenosis will be excluded from the overall study. 13. Participation in a research study that conflicts with the current WISE study. 14. Women with coronary stenosis ≥ 50% in any epicardial coronary artery, assessed visually at the time of angiography, will not be included in the CRT subgroup.

Additional Information

Official title Women's Ischemia Syndrome Evaluation (WISE) Coronary Vascular Dysfunction
Principal investigator C. Noel Bairey Merz, MD, FACC
Description See Brief Summary above.
Trial information was received from ClinicalTrials.gov and was last updated in March 2017.
Information provided to ClinicalTrials.gov by Cedars-Sinai Medical Center.